Natural and synthetic growth hormone secretagogues: Do they have therapeutic potential?

Treatments in Endocrinology

Volumn 2, Issue 3, 2003, Pages 153-163

  Broglio, F ^a   Arvat, E ^a   Gottero, C ^a   Benso, A ^a   Prodam, F ^a   Destefanis, S ^a   Aimaretti, G ^a   Papotti, M ^b   Muccioli, G ^b   Deghenghi, R ^a   Ghigo, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; APPETITE STIMULANT; GHRELIN; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; GROWTH PROMOTOR; IBUTAMOREN; PROLACTIN;

ACYLATION; APOPTOSIS; BEHAVIOR; CARDIOVASCULAR EFFECT; CELL PROLIFERATION; ENDOCRINE FUNCTION; GLUCOSE METABOLISM; GONAD FUNCTION; GROWTH HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; INSULIN RELEASE; METABOLISM; NEUROENDOCRINOLOGY; PANCREAS FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN ANALYSIS; REJUVENATION; REPRODUCIBILITY; REVIEW; SLEEP;

ANIMALS; ENDOCRINE SYSTEM; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; PEPTIDE HORMONES;

EID: 0038303397     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200302030-00002     Document Type: Review

References (119)

1. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717-97
2. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60
3. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab 2001; 86: 1464-9
4. Kojima M, Hosoda H, Matsuo H, et al. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 2001; 12: 118-22
5. Kojima M, Hosoda H, Kangawa K. Purification and distribution of ghrelin: the natural endogenous ligand for the growth hormone secretagogue receptor. Horm Res 2001; 56 Suppl. 1: 93-7
6. Muccioli G, Tschop M, Papotti M, et al. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002 Apr 12; 440 (2-3): 235-54
7. Smith RG, van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997; 18: 621-45
8. Ghigo E, Arvat E, Aimaretti G, et al. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Baillières Clin Endocrinol Metab 1998; 12: 341-58
9. Bowers CY, Alster DK, Frentz JM. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab 1992 Feb; 74(2): 292-8
10. Yoshihara F, Kojima M, Hosoda H, et al. Ghrelin: a novel peptide for growth hormone release and feeding regulation. Curr Opin Clin Nutr Metab Care 2002 Jul; 5 (4): 391-5
11. Fehrentz JA, Martinez J, Boeglin D, et al. Growth hormone secretagogues: past. present and future. I Drugs 2002; 5 (8): 804-14
12. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-0677) in healthy elderly subjects. J Clin Endocrinol Metab 1996 Dec; 81 (12): 4249-57
13. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996 Aug 16; 273 (5277): 974-7
14. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 2002 Jun; 87 (6): 2988-91
15. Horvath TL, Diano S, Sotonyi P, et al. Ghrelin and the regulation of energy homeostasis: a hypothalamic perspective. Endocrinology 2001; 142: 4163-9
16. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001; 2: 551-60
17. Bednarek MA, Feighner SD, Pong SS, et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 2000; 43: 4370-6
18. Muccioli G, Papotti M, Locatelli V, et al. Binding of 1251-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 2001; 24: RC7-9
19. Matsumoto M, Hosoda H, Kitajima Y, et al. Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun 2001; 287: 142-6
20. Banks WA, Tschop M, Robinson S, et al. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 2002 Aug; 302 (2): 822-7
21. Hosoda H, Kojima M, Matsuo H, et al. Purification and characterization of rat des-Gln14-ghrelin, a second endogenous ligand for the growth hormone secretagogue receptor. J Biol Chem 2000 Jul 21; 275 (29): 21995-2000
22. Smith RG, Griffin PR, Xu Y, et al. Adenosine: a partial agonist of the growth hormone secretagogue receptor. Biochem Biophys Res Commun 2000 Oct 5; 276 (3): 1306-13
23. Tullin S, Hansen BS, Ankersen M, et al. Adenosine is an agonist of the growth hormone secretagogue receptor. Endocrinology 2000 Sep; 141 (9): 3397-402
24. Deghenghi R, Papotti M, Ghigo E, et al. Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland. J Endocrinol Invest 2001; 24: RC1-3
25. Smith RG, Leonard R, Bailey AR, et al. Growth hormone secretagogue receptor family members and ligands. Endocrine 2001 Feb; 14 (I): 9-14
26. Tolle V, Bassant M, Zizzari P, et al. Ultradian rhythmicity of ghrelin secretion in relation with GH feeding behavior, and sleep-wake patterns in rats. Endocrinology 2002 Apr; 143 (4): 1353-61
27. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-9
28. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-9
29. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001 Oct; 86 (10): 4753-8
30. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:21 1623-30
31. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 244
32. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145: R5-9
33. Hansen TK, Dall R, Hosoda H, et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 2002; 56: 203-6
34. Altman J. Weight in the balance. Neuroendocrinology 2002; 76: 131-6
35. Tschop M, Wawarta R, Riepl RL, et al. Post-prandial decrease of circulating human ghrelin levels. J Endocrinol Invest 2001 Jun; 24 (6): RC19-21
36. McCowen KC, Maykel JA, Bistrian BR, et al. Circulating ghrelin concentrations are lowered by intravenous glucose or hyperinsulinemic euglycemic conditions in rodents. J Endocrinol 2002 Nov; 175 (2): R7-R11
37. Nakagawa E, Nagaya N, Okumura H, et al. Hyperglycaemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide: responses to the intravenous and oral administration of glucose. Clin Sci 2002 Sep; 103 (3): 325-8
38. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001 Aug; 50 (8): 1714-9
39. Bellone S, Rapa A, Vivenza D, et al. Circulating ghrelin levels as function of gender, pubertal status and adiposity in childhood. J Endocrinol Invest 2002; 25: RC13-5
40. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001 Oct; 86 (10): 5083-6
41. Saad MF, Bernaba B, Hwu CM, et al. Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 2002 Aug; 87 (8): 3997-4000
42. Egido EM, Rodriguez-Gallardo J, Silvestre RA, et al. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur J Endocrinol 2002 Feb; 146 (2): 241-4
43. Pagotto U, Gambineri A, Vicennati V, et al. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 2002 Dec; 87 (12): 5625-9
44. Ikezaki A, Hosoda H, Ito K, et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 2002 Dec; 51 (12): 3408-11
45. Lucidi P, Murdolo G, Di Loreto C, et al. Ghrelin is not necessary for adequate hormonal counterregulation of insulin-induced hypoglycemia. Diabetes 2002 Oct; 51 (10): 2911-4
46. Broglio F, Koetsveld Pv P, Benso A, et al. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans. J Clin Endocrinol Metab 2002 Oct; 87 (10): 4829-32
47. Cummings DE, Clement K, Purnell JQ, et al. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med 2002; 8: 643-4
48. del Parigi A, Tschop M, Heiman ML, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2002; 87: 5461-4
49. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000; 85: 4908-11
50. Arvat E, Di Vito L, Broglio F, et al. Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest 2000; 23: 493-5
51. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001; 86: 1169-74
52. Bluet-Pajot MT, Tolle V, Zizzari P, et al. Growth hormone secretagogues and hypothalamic networks. Endocrine 2001 Feb; 14 (1): 1-8
53. Wren AM, Small CJ, Fribbens CV, et al. The hypothalamic mechanisms of the hypophysiotropic action of ghrelin. Neuroendocrinology 2002 Nov; 76 (5): 316-24
54. Maheshwari HG, Rahim A, Shalet SM, et al. Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency. J Clin Endocrinol Metab 1999 Mar; 84: 956-9
55. Hataya Y, Akazimu T, Takaya K, et al. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J Clin Endocrinol Metab 2001; 86: 4552-5
56. Tannenbaum GS, Bowers CY. Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin. Endocrine 2001 Feb; 14 (1): 21-7
57. Di Vito L, Broglio F, Benso A, et al. The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clin Endocrinol (Oxf) 2002 May; 56 (5): 643-8
58. Broglio F, Benso A, Gottero C, et al. Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans. Clin Endocrinol 2002 Aug; 57 (2): 265-71
59. Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 2000; 356: 1137-42
60. Baldelli R, Otero XL, Camina JP, et al. Growth hormone secretagogues as diagnostic tools in disease state. Endocrine 2001 Feb; 14 (1): 95-9
61. Shalet SM, Toogood A, Rahim A, et al. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998; 19: 203-23
62. Ghigo E, Aimaretti G, Arvat E, et al. Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine 2001 Jun; 15 (1): 29-38
63. Laron Z, Frenkel J, Deghenghi R, et al. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf) 1995; 43: 631-5
64. Mericq V, Cassorla F, Garcia H, et al. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J Clin Endocrinol Metab 1995; 80: 1681-4
65. Klinger B, Silbergeld A, Deghenghi R, et al. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996; 134: 716-9
66. Pihoker C, Badger TM, Reynolds GA, et al. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol 1997; 155: 79-86
67. Laron Z. Intranasally and orally active GH secretagogues are useful clinical tools: so why are they not on the market? J Endocrinol Invest 2003 Jan; 26: 91-2
68. Yu H, Cassorla F, Tiulpakov A, et al. A double-blind placebo-controlled efficacy trial of an oral growth hormone (GH) secretagogue (MK-0677) in GH deficient (GHD) children [abstract]. The 80th Annual Meeting of the Endocrine Society's; 1998 Jun 24-27; New Orleans, 84
69. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39
70. Ghigo E, Arvat E, Gianotti L, et al. Human aging and the GH-IGF-I axis. J Pediatr Endocrinol Metab 1996; 9: 271-8
71. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998; 83: 320-5
72. Svensson J, Lonn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998; 83: 362-9
73. Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001; 86: 1116-25
74. Ishizaki S, Murase T, Sugimura Y, et al. Role of ghrelin in the regulation of vasopressin release in conscious rats. Endocrinology 2002 May; 143 (5): 1589-93
75. Korbonits M, Bustin SA, Kojima M, et al. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86: 881-7
76. Tena-Sempere M, Barreiro ML, Gonzalez LC, et al. Novel expression and functional role of ghrelin in rat testis. Endocrinology 2002 Feb; 143 (2): 717-25
77. Furuta M, Funabashi T, Kimura F. Intracerebroventricular administration of ghrelin rapidly suppresses pulsatile luteinizing hormone secretion in ovariectomized rats. Biochem Biophys Res Commun 2001 Nov 9; 288 (4): 780-5
78. Volante M, Allia E, Gugliotta P, et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2002 Mar; 87 (3): 1300-8
79. Date Y, Nakazato M, Hashiguchi S, et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002 Jan; 51 (1): 124-9
80. Wierup N, Svensson H, Mulder H, et al. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept 2002 Jul 15; 107 (1-3): 63-9
81. Adeghate E, Ponery AS. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J Neuroendocrinol 2002 Jul; 14 (7): 555-60
82. Lee HM, Wang G, Englander EW, et al. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 2002 Jan; 143 (1): 185-90
83. Murata M, Okimura Y, Iida K, et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002 Feb 15; 277 (7): 5667-74
84. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation 2001 Oct 23; 104 (17): 2034-8
85. Torsello A, Locatelli V, Melis MR, et al. Differential orexigenic effects of hexarelin and its analogs in the rat hypothalamus: indication for multiple growth hormone secretagogue receptor subtypes. Neuroendocrinology 2000 Dec; 72 (6): 327-32
86. Cone RD, Cowley MA, Butler AA, et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001 Dec; 25 Suppl. 5: S63-7
87. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001 Jan 11; 409 (6817): 194-8
88. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001 Feb; 50 (2): 227-32
89. Lawrence CB, Snape AC, Baudoin FM, et al. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology 2002 Jan; 143 (1): 155-62
90. Tschop M, Statnick MA, Suter TM, et al. GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology 2002 Feb; 143 (2): 558-68
91. Date Y, Kojima M, Hosoda H, et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000; 141: 4255-61
92. Shuto Y, Shibasaki T, Wada K, et al. Generation of polyclonal antiserum against the growth hormone secretagogue receptor (GHS-R): evidence that GHS-R exists in the hypothalamus, pituitary and stomach of rats. Life Sci 2001; 68: 991-6
93. Folwaczny C, Chang JK, Tschop M. Ghrelin and motilin: two sides of one coin? Eur J Endocrinol 2001 Apr; 144 (4): R1-3
94. Zhang W, Chen M, Chen X, et al. Inhibition of pancreatic protein secretion by ghrelin in the rat. J Physiol 2001 Nov 15; 537 (Pt 1): 231-6
95. Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI3-kinase/AKT. J Cell Biol 2002 Dec 16 23; 159 (6): 1029-37
96. Pettersson I, Muccioli G, Granata R, et al. Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol 2002 Oct; 175 (1): 201
97. Rossoni G, De Gennaro Colonna V, Bernareggi M, et al. Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharmacol 1998 Aug; 32 (2): 260-5
98. De Gennaro Colonna V, Rossoni G, Bernareggi M, et al. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. Cardiologia 1997 Nov; 42 (11): 1165-72
99. Bresciani E, Rossoni G, Torsello A, et al. Ghrelin cardioprotective effects in the rat: comparison with hexarelin. The 80th Annual Meeting of the Endocrine Society; 1998 June 24-27; New Orleans, P1:165
100. Tivesten A, Bollano E, Caidahl K, et al. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000; 141: 60-6
101. Weekers F, Van Herck E, Isgaard J, et al. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Endocrinology 2000; 141: 3993-9
102. King MK, Gay DM, Pan LC, et al. Treatment with a growth hormone secretagogue in a model of developing heart failure: effects on ventricular and myocyte function. Circulation 2001; 103: 308-12
103. Bodart V, Bouchard JF, McNicoll N, et al. Identification and chacterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 1999; 85: 796-808
104. Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002 May 3; 90 (8): 844-9
105. Bisi G, Podio V, Valetto MR, et al. Acute cardiovascular and hormonal effect of GH and hexarelin a synthetic GH-releasing peptide, in humans. J Endocrinol Invest 1999 Apr; 22 (4): 266-72
106. Bisi G, Podio V, Valetto MR, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999 Sep 17; 381 (1): 31-8
107. Imazio M, Bobbio M, Broglio F, et al. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. Eur J Heart Fail 2002 Mar; 4 (2): 185-91
108. Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483-7
109. Nagaya N, Miyatake K, Uematsu M, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001 Dec; 86 (12): 5854-9
110. Cassoni P, Papotti M, Catapano F, et al. Specific binding sites for synthetic growth hormone secretagogues in non-tumoral and neoplastic human thyroid tissue. J Endocrinol 2000 Apr; 165 (1): 139-46
111. Cassoni P, Papotti M, Ghe C, et al. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines. J Clin Endocrinol Metab 2001; 86: 1738-45
112. Ghe C, Cassoni P, Catapano F, et al. The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells. Endocrinology 2002 Feb; 143 (2): 484-91
113. Jeffery PL, Herington AC, Chopin LK. Expression and action of the growth hormone releasing peptide ghrelin and its receptor in prostate cancer cell lines. J Endocrinol 2002 Mar; 172 (3): R7-11
114. Copinschi G, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profile insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996 Aug; 81 (8): 2776-82
115. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998 Sep 15; 21 (6): 553-66
116. Tolle V, Bassant MH, Zizzari P, et al. Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behaviour, and sleep awake patterns in rats. Endocrinology 2002; 143: 1353-61
117. Weikel JC, Wichniak A, Ising M. Ghrelin promotes slow-wave sleep in man. Am J Physiol Endocrinol Metab 2003 Feb; 284 (2): E4078-415
118. Carlini VP, Monzon ME, Varas MM, et al, Ghrelin increases anxiety-like behavior and memory retention rats. Biochem Biophys Res Commun 2002 Dec 20; 299 (5): 739-43
119. Asakawa A, Inui A, Kaga T, et al. A role of ghrelin in neuroendocrine and behavioral response to stress in mice. Neuroendocrinology 2001; 74: 143-7